Pindong Li

Final results of a phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC).

M. Jin, Shengli Yang, Junli Liu, Jieying Zhang et autres

395 Background: Second-line treatment options for advanced gastric cancer remain limited. This open-label, single-arm phase II study (NCT05625737) aimed to identify the efficacy and safety of fruquintinib (VEGFR-1, -2, -3 inhibitor) plus sintilimab (anti-PD-1) as second-line therapy in GC/GEJC. Here we report …

hk, cn (code pays fourni par la source)

Fruquintinib and pirfenidone in combination with anti-PD-1 antibody in pMMR/MSS metastatic colorectal carcinoma: A prospective, single-arm, phase Ib/II trial.

Zhenyu Lin, Haihong Wang, Linlin Zheng, Zhao Lu et autres

123 Background: The combination of fruquintinib and anti-PD-1 has synergistic anti-tumor effects. However, liver metastases diminish immunotherapy efficacy systemically in patients and preclinical models. Our previous study had proved that anti-fibrotic agent pirfenidone combined with anti-PD-1 can enhance the therapeutic efficacy of …

cn, hk (code pays fourni par la source)

Case Report: Sequential PTCD and biliary seed stent combined with targeted-immunotherapy for advanced pancreatic cancer with malignant obstructive jaundice: a multidisciplinary approach

Weijun Li, Guoyang Sun, Rui Zhu, Pindong Li et autres

Malignant obstructive jaundice (MOJ) due to tumor compression or invasion of the bile duct carries a grave prognosis. We report a case of a 54-year-old female patient (height: 160 cm, weight: 55 kg, BMI: 21.5 kg/m², ECOG performance status: 1, with type …

cn (code pays fourni par la source)

A phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results.

Min Jin, Shengli Yang, Junli Liu, Jieying Zhang et autres

407 Background: Preliminary results of the open-label, single-arm phase II study (NCT05625737) had demonstrated the combination of fruquintinib and sintilimab as a second-line therapy had a promising anti-tumor activity and an acceptable safety profile in pts with advanced GC/GEJC (ASCO-GI 2024. Poster …

hk, cn (code pays fourni par la source)

Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study

Mingxia Cheng, Min Jin, Shengli Yang, Lei Zhao et autres

BACKGROUND: Immune checkpoint inhibitors (ICIs) in combination with antiangiogenic drugs have shown promising outcomes in the third-line and subsequent treatments of patients with microsatellite stable metastatic colorectal cancer (MSS-mCRC). Radiotherapy (RT) may enhance the antitumor effect of immunotherapy. However, the effect of …

hk, cn (code pays fourni par la source)

Factors associated with HPV vaccine hesitancy among college students: A cross-sectional survey based on 3Cs and structural equation model in China

Cheng Chen, Ting Chen, Mingzhao Huang, Yan Huang et autres

Despite the high effectiveness of HPV vaccines in preventing infection, vaccine hesitancy remains a concern, particularly in China. This study aimed to explore college students' attitudes toward HPV vaccination and identify associated factors. Data was collected through a cross-sectional survey using self-administered …

cn, hk, us (code pays fourni par la source)

Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single-arm, prospective study.

Min Jin, Shengli Yang, Junli Liu, Jieying Zhang et autres

332 Background: The KEYNOTE-061 trial showed that anti-PD-1 monotherapy did not improve overall survival compared to chemotherapy in the second-line treatment of advanced GC/GEJC. Preclinical and clinical data have demonstrated the synergistic anti-tumor effect of fruquintinib, a highly selective oral VEGFR 1/2/3 …

hk, cn (code pays fourni par la source)

Abstract LB302: Radiotherapy exposure and baseline gut microbiota predict clinical outcomes of fruquintinib plus sintilimab in microsatellite-stable metastatic colorectal cancer

Min Jin, Mingxia Cheng, Shengli Yang, Lei Zhao et autres

Abstract Background: Clinical trials demonstrated that immune checkpoint inhibitors (ICIs) combined with antiangiogenic drugs had achieved promising outcomes in the third-line and further treatment in metastatic colorectal cancer (mCRC) patients (pts) with microsatellite-stable (MSS) or proficient mismatch repair. Radiotherapy (RT) may enhance …

cn (code pays fourni par la source)

Deficiency of Carbamoyl Phosphate Synthetase 1 Engenders Radioresistance in Hepatocellular Carcinoma via Deubiquitinating c-Myc

Sisi Zhang, Yue Hu, Zilong Wu, Xiaoshu Zhou et autres

hk, cn (code pays fourni par la source)

Efficacy and safety of neoadjuvant therapy with stereotactic body radiation therapy followed by nab-paclitaxel/gemcitabine plus camrelizumab for resectable, borderline resectable and locally advanced pancreatic cancer: Preliminary results.

Jun Wu Xue, Yue Hu, Shanmiao Gou, Tao Yin et autres

e16227 Background: Neoadjuvant therapy has been attempted to improve local control and prolong survival for pancreatic cancer patients. However, the standard treatment has not been defined. This trial was to evaluate the efficacy and safety of nab-paclitaxel/gemcitabine plus camrelizumab with or without …

hk, cn (code pays fourni par la source)

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Bi‐Cheng Wang, Bo‐Ya Xiao, Pengcheng Li, Bo‐Hua Kuang et autres

[This corrects the article DOI: 10.1155/2020/2368164.].

hk, cn (code pays fourni par la source)

Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

Bi‐Cheng Wang, Bo‐Ya Xiao, Pengcheng Li, Bo‐Hua Kuang et autres

BACKGROUND: The prognosis of patients with extensive-stage small cell lung cancer (SCLC) is poor. Adding an immune checkpoint inhibitor (ICI) to chemotherapy may exert a synergistic effect and improve survival outcomes. However, for treatment-naive extensive-stage SCLC patients, the efficacy of immunotherapy in …

hk, cn (code pays fourni par la source)